Generic Name and Formulations:
Polidocanol 1% (1.3mg/mL); foam for IV inj after activation.
Indications for VARITHENA:
Treatment of incompetent great saphenous veins (GSV), accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee.
See full labeling. For IV inj using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct inj into varicosities. Use up to 5mL per injection and max 15mL per treatment session. Inject foam slowly (approx. 1mL/sec in the GSV and 0.5mL/sec in accessory veins or varicosities). Repeat if necessary; separate treatment sessions by a minimum of 5 days. Apply compression bandaging and stockings and have the patient walk for at least 10mins; monitor. Maintain compression for 2 weeks post-treatment.
Acute thromboembolic disease.
Do not inject intra-arterially. Must be experienced in venous procedures. Monitor for at least 10mins post-inj for anaphylaxis; treat appropriately if occurs. Increased risk of tissue ischemia in peripheral arteriosclerosis or thromboangiitis obliterans (Buerger’s Disease). Monitor for venous thrombosis post-treatment. Increased risk of thrombosis in patients with reduced mobility, history of DVT/PE, major surgery within 3 months, prolonged hospitalization, pregnancy. Labor & delivery. Pregnancy (Cat.C), nursing mothers: not recommended.
Pain/discomfort in extremity, infusion site thrombosis (retained coagulum), injection site hematoma or pain, thrombophlebitis superficial, extravasation; anaphylaxis (may be fatal).
Convenience box—1 (w. canisters, transfer units, administration boxes); Bi-canister—1; Administration pack—1 (transfer unit, components)
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|